Pink Sheet“Pipeline in a pill”-style drug development will be on display in April, when more than half of the user fee goal dates are for new indications on sometimes sprawling labels, as well as one novel biol
Pink SheetThe disruption of existing markets is a dominant ambition of the nearly 20 applications expecting US Food and Drug Administration action in March. The Pink Sheet ’s US FDA Performance Tracker shows
Pink SheetThe novel candidates under US Food and Drug Administration review in oncology and neuroscience, its two biggest pending therapy areas, highlight the deep inroads precision medicine has made in contemp
Pink SheetSeikagaku Corporations ’s radicular leg pain treatment should be approved as long as the drug label is narrower than currently proposed and includes tight safety controls, a US Food and Drug Administr